GR-1802 is under clinical development by Genrix (Shanghai) Biopharmaceutical and currently in Phase II for Seasonal Allergic Rhinitis. According to GlobalData, Phase II drugs for Seasonal Allergic Rhinitis have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GR-1802’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GR-1802 overview
GR-1802 is under development for the treatment of atopic dermatitis, moderate to severe asthma, chronic spontaneous urticaria, chronic sinusitis with nasal polyps, seasonal allergic rhinitis and chronic rhinosinusitis with nasal polyps. The drug candidate is administered through subcutaneous route and acts by targeting interleukin 4 receptor alpha (IL4Ra).
Genrix (Shanghai) Biopharmaceutical overview
Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd (Zhixiang Pharmaceutical) is an innovation-driven biotechnology company. The company’s business area is the research and development and industrialization of therapeutic monoclonal antibodies and fusion proteins and other biotechnology drugs. Zhixiang Pharmaceutical is headquartered in Shanghai, China.
For a complete picture of GR-1802’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
